NIDA - About NIDA - Organization - NACDA Offices - ARP

Racial/ethnic disparities in HIV testing and access and utilization of treatment and services
Improving HIV therapy by studying: ART interactions with drugs of abuse and drug abuse treatment medications, development of ART drug resistance
Improving access, utilization, adherence, and effectiveness of HIV therapy
Spread of HIV among drug users and their networks
Role of non-injection drug use in facilitating HIV transmission through sexual risk behaviors (MSM and heterosexuals)
Prevention interventions among drug users involved in the criminal justice system
Research on adolescent development, decision-making, impulsivity
Intervention strategies to coordinate and improve treatment and services for HIV, drug abuse, and co-occurring conditions (e.g., HCV)
Medical consequences of HIV/AIDS, drug use, comorbid conditions, and HIV treatment
Enhanced testing and counseling strategies
Drug abuse, HIV, and the brain
Genetics and proteomic studies in drug abusers and/or animal models of HIV
Research on structural interventions to prevent HIV/AIDS transmission and/or to enhance access/utilization of treatment and services
Support training of new AIDS researchers

Develop prevention strategies addressing non-injection drug use such as stimulants (e.g., methamphetamine, cocaine, crack) in vulnerable populations (e.g., MSM, young women) where prevalence of HIV infection is high (e.g., Latin America)
Develop prevention strategies addressing HIV/injection drug use epidemics in different geographic areas (Russia, China, SE Asia, India, Eastern/Central Europe)
Develop regional research networks
Develop new methods for gathering HIV epidemiological data and tracking HIV diffusion
Assess role of immigration and migration in drug abuse and HIV transmission
Assessment of drug treatment as HIV prevention, including development of long-acting, sustainable therapies
Assessment of HIV/AIDS treatment as HIV prevention
HIV and co-infections (e.g., HCV, TB)